ONCOLYTICS BIOTECH INC (ONCY) Fundamental Analysis & Valuation
NASDAQ:ONCY • CA6823108759
Current stock price
0.9004 USD
-0.07 (-7.05%)
At close:
0.9189 USD
+0.02 (+2.05%)
After Hours:
This ONCY fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. ONCY Profitability Analysis
1.1 Basic Checks
- In the past year ONCY has reported negative net income.
- In the past year ONCY has reported a negative cash flow from operations.
- In the past 5 years ONCY always reported negative net income.
- ONCY had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- The Return On Assets of ONCY (-152.26%) is worse than 84.85% of its industry peers.
- With a Return On Equity value of -499.46%, ONCY is not doing good in the industry: 78.45% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -152.26% | ||
| ROE | -499.46% | ||
| ROIC | N/A |
ROA(3y)-98.37%
ROA(5y)-83.59%
ROE(3y)-241.47%
ROE(5y)-177.64%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- ONCY does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. ONCY Health Analysis
2.1 Basic Checks
- Compared to 1 year ago, ONCY has more shares outstanding
- The number of shares outstanding for ONCY has been increased compared to 5 years ago.
- The debt/assets ratio for ONCY is higher compared to a year ago.
2.2 Solvency
- ONCY has an Altman-Z score of -32.16. This is a bad value and indicates that ONCY is not financially healthy and even has some risk of bankruptcy.
- Looking at the Altman-Z score, with a value of -32.16, ONCY is doing worse than 89.90% of the companies in the same industry.
- A Debt/Equity ratio of 0.10 indicates that ONCY is not too dependend on debt financing.
- With a Debt to Equity ratio value of 0.10, ONCY is not doing good in the industry: 63.50% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -32.16 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- A Current Ratio of 2.88 indicates that ONCY has no problem at all paying its short term obligations.
- ONCY has a Current ratio of 2.88. This is in the lower half of the industry: ONCY underperforms 64.08% of its industry peers.
- A Quick Ratio of 2.88 indicates that ONCY has no problem at all paying its short term obligations.
- ONCY's Quick ratio of 2.88 is on the low side compared to the rest of the industry. ONCY is outperformed by 62.14% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.88 | ||
| Quick Ratio | 2.88 |
3. ONCY Growth Analysis
3.1 Past
- ONCY shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -8.36%.
EPS 1Y (TTM)-8.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.74%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- Based on estimates for the next years, ONCY will show a very strong growth in Earnings Per Share. The EPS will grow by 37.86% on average per year.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y21.99%
EPS Next 2Y6.67%
EPS Next 3Y10.11%
EPS Next 5Y37.86%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. ONCY Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for ONCY. In the last year negative earnings were reported.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ONCY. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.67%
EPS Next 3Y10.11%
5. ONCY Dividend Analysis
5.1 Amount
- No dividends for ONCY!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
ONCY Fundamentals: All Metrics, Ratios and Statistics
0.9004
-0.07 (-7.05%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-05 2026-03-05/amc
Earnings (Next)05-01 2026-05-01
Inst Owners2.24%
Inst Owner Change0%
Ins Owners3.22%
Ins Owner Change17.1%
Market Cap104.56M
Revenue(TTM)N/A
Net Income(TTM)-30.41M
Analysts77.5
Price TargetN/A
Short Float %5.71%
Short Ratio5.31
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)27.91%
Min EPS beat(2)20.79%
Max EPS beat(2)35.03%
EPS beat(4)3
Avg EPS beat(4)14.8%
Min EPS beat(4)-15.35%
Max EPS beat(4)35.03%
EPS beat(8)6
Avg EPS beat(8)14.12%
EPS beat(12)8
Avg EPS beat(12)8.97%
EPS beat(16)11
Avg EPS beat(16)10.72%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 23.36 | ||
| P/tB | 23.36 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.29
EYN/A
EPS(NY)-0.26
Fwd EYN/A
FCF(TTM)-0.16
FCFYN/A
OCF(TTM)-0.16
OCFYN/A
SpS0
BVpS0.04
TBVpS0.04
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -152.26% | ||
| ROE | -499.46% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-98.37%
ROA(5y)-83.59%
ROE(3y)-241.47%
ROE(5y)-177.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 9.64% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.88 | ||
| Quick Ratio | 2.88 | ||
| Altman-Z | -32.16 |
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)24.58%
Cap/Depr(5y)28.97%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-8.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.74%
EPS Next Y21.99%
EPS Next 2Y6.67%
EPS Next 3Y10.11%
EPS Next 5Y37.86%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y15.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-63.16%
EBIT Next 3Y5.76%
EBIT Next 5Y0.67%
FCF growth 1Y6.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y6.92%
OCF growth 3YN/A
OCF growth 5YN/A
ONCOLYTICS BIOTECH INC / ONCY Fundamental Analysis FAQ
What is the ChartMill fundamental rating of ONCOLYTICS BIOTECH INC (ONCY) stock?
ChartMill assigns a fundamental rating of 1 / 10 to ONCY.
What is the valuation status of ONCOLYTICS BIOTECH INC (ONCY) stock?
ChartMill assigns a valuation rating of 0 / 10 to ONCOLYTICS BIOTECH INC (ONCY). This can be considered as Overvalued.
Can you provide the profitability details for ONCOLYTICS BIOTECH INC?
ONCOLYTICS BIOTECH INC (ONCY) has a profitability rating of 0 / 10.